Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation

Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation

Objectives Currently, there is limited understanding regarding the prognostic significance of time to progression (TTP) after first remission in multiple myeloma (MM).Methods We conducted a retrospective analysis of clinical data from 209 patients with MM. These patients were categorized into ≤ 6 mo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yanhua Yue, Yingjie Miao, Yifang Zhou, Yangling Shen, Luo Lu, Fei Wang, Yang Cao, Bai He, Weiying Gu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Hematology
Subjects:	Multiple myeloma ‌first remission ‌myeloma progression time to progression ‌post-progression treatment ‌autologous hematopoietic stem cell transplantation
Online Access:	https://www.tandfonline.com/doi/10.1080/16078454.2024.2448024
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Autologous Hematopoietic Cell Transplant as an Effective Treatment Modality for Systemic Sclerosis and Multiple Myeloma
by: Memon H, et al.
Published: (2025-01-01)

Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma
by: Kaili Chen, et al.
Published: (2025-01-01)

Tandem Versus Single Autologous Stem Cell Transplantation for High‐Risk Multiple Myeloma in the Era of Novel Agents: A Real‐World Study of China
by: Xuelin Dou, et al.
Published: (2025-01-01)

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)

Predictive factors of thrombosis during autologous stem cell transplantation in multiple myeloma: Experience from EHU Oran (Algeria)
by: Mohammed Amine BEKADJA, et al.
Published: (2022-06-01)

Predictive factors of thrombosis during autologous stem cell transplantation in multiple myeloma: Experience from EHU Oran (Algeria)
by: Mohammed Amine BEKADJA, et al.
Published: (2022-06-01)

Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy
by: Gianluca Cavallaro
Published: (2024-04-01)

Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group
by: Anna Waszczuk-Gajda, et al.
Published: (2020-04-01)

Comparison of autologous hematopoietic cell transplantation, matched sibling donor hematopoietic cell transplantation, and chemotherapy in patients with favorable- and intermediate-risk acute myeloid leukemia
by: Mingyang Wang, et al.
Published: (2025-01-01)

Sintilimab for treating progressive multifocal leukoencephalopathy caused by human polyomavirus 2 virus infection following allogeneic hematopoietic cell transplantation: a case report
by: Xuelian Jin, et al.
Published: (2025-12-01)

Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
by: Annemarie Glöckner, et al.
Published: (2025-01-01)

Oral manifestations of multiple myeloma – A systematic review
by: Padmajaa Krishnan, et al.
Published: (2024-06-01)

Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
by: Kara I. Cicero, et al.
Published: (2025-01-01)

Modified screening and management strategies for chronic rhinosinusitis in hematologic patients receiving hematopoietic stem cell transplantation
by: Yen-Hui Lee, et al.
Published: (2025-02-01)

Haploidentical hematopoietic stem cell transplantation using post-transplant cyclophosphamide in patients with inborn errors of immunity: Experience in a reference center in Colombia
by: Diego Medina, et al.
Published: (2024-12-01)

Autologous osteoperiosteal transplantation achieves comparable repair effect and superior interface integration to autologous osteochondral transplantation in porcine osteochondral defects
by: Shuai Yang, et al.
Published: (2025-03-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

Clinical Characteristics and Prognostic Factors Affecting Clinical Outcomes in Cytomegalovirus Retinitis Following Allogeneic Hematopoietic Stem Cell Transplantation
by: Qiaozhu Zeng, et al.
Published: (2025-01-01)

Exploring hematopoietic stem cell awareness and engagement among healthcare professionals: A cross-sectional survey
by: Vikash Chandra Mishra, et al.
Published: (2024-12-01)

Effect of Hematopoietic Stem Cell Transplantation Regimen on Tacrolimus Pharmacokinetics
by: Haruno Oku, BS, et al.
Published: (2025-01-01)

Chromothripsis in Treatment Resistance in Multiple Myeloma
by: Kyoung Joo Lee, et al.
Published: (2017-09-01)

CRANIOFACIAL DEFORMITIES TREATED BY AUTOLOGOUS FAT TRANSPLANTATION TECHNIQUE: CROSS-SECTIONAL STUDY
by: Cristian Drochioi, et al.
Published: (2024-12-01)

Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram
by: Yanjuan Li, et al.
Published: (2025-01-01)

BİLİMSEL İLERLEME NEDİR?
by: Ercan Salgar
Published: (2015-12-01)

The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib
by: Yoshiya Tanaka, et al.
Published: (2024-11-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

A Rare Case of Superior Mesenteric Artery Thrombosis in Multiple Myeloma
by: Jasminder Singh, et al.
Published: (2024-12-01)

Hematopoietic stem cell transplantation as rescue therapy for refractory autoimmune retinopathy: a case report
by: Wendy Meihua Wong, et al.
Published: (2025-01-01)

A finite-element approach for the analysis of pin-bearing failure of composite laminates
by: Michele Marino, et al.
Published: (2014-07-01)

Modified autologous neurosensory retinal transplantation and bevacizumab injection in primary extra-large chronic macular holes
by: Hossein Ashraf, et al.
Published: (2025-06-01)

Progress and Criticism of Progress as a Characteristic of Modern Civilizations in the Work of Friedrich Nietzsche and Ludwig Wittgenstein
by: Ulrich Arnswald
Published: (2024-10-01)

Monocyte‐predominant engraftment, cytokine levels and early transplant‐related complications in pediatric hematopoietic stem cell recipients
by: Natalia Maximova, et al.
Published: (2019-03-01)

LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM?
by: Fabian Herrera
Published: (2024-04-01)

Evaluation of plasma cell sorting methods in multiple myeloma patients: flow cytometry versus magnetic beads
by: Yu Jeong Choi, et al.
Published: (2025-01-01)

Advances in allogeneic hematopoietic stem cell transplantation for Langerhans cell histiocytosis in children
by: Guangqiang Meng, et al.
Published: (2025-01-01)

Rapid Progression of Plasmacytoma to Multiple Myeloma after Cervical Laminectomy
by: Dudung Lupito, et al.
Published: (2024-12-01)

Incorporation and Effect of Arachidonic Acid on the Growth of Human Myeloma Cell Lines
by: V. Desplat, et al.
Published: (1999-01-01)

Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions
by: Muhammad Azhar Ud Din, et al.
Published: (2025-01-01)

Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada
by: Matthew D. Seftel, et al.
Published: (2024-12-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01)